Bio Break: Understanding Continuous Glucose Monitors
Continuous glucose monitors (CGMs) are revolutionizing how people track blood sugar levels in real time. But how do they work, and where exactly do they measure glucose? In this episode of Bio Break, Nick and Joris explore the science behind CGMs, explaining the difference between blood glucose monitoring and interstitial fluid measurement—and why CGMs don’t actually draw blood continuously.
Rather than inserting a sensor directly into a vein, CGMs use microneedles or tiny tubes that sit in the interstitial fluid, the liquid surrounding the body’s cells. Unlike blood, which flows within veins, interstitial fluid is more accessible for continuous monitoring. However, there’s a key tradeoff—glucose levels in interstitial fluid lag behind blood glucose levels by about 5-10 minutes. This means CGMs don’t provide an instant blood sugar reading but rather a near-real-time estimate.
Nick raises an important question: does this time lag matter for diabetes management or sports performance tracking? Joris explains that while this delay exists, CGMs still offer huge advantages over traditional blood testing, which often requires finger pricks or lab draws that provide only a single data point. The ability to continuously measure glucose, lactate, or other small molecules gives users a clearer picture of how their body responds to food, exercise, and lifestyle changes.
However, not everything can be measured using interstitial fluid. Large molecules like hormones, red blood cells, and protein-bound compounds don’t diffuse as easily into interstitial fluid, making them difficult to track with a CGM. But for small molecules such as glucose, lactate, histamine, and creatinine, interstitial fluid monitoring is a powerful tool for real-time insights into metabolism.
If you’ve ever wondered how CGMs work or why they don’t require direct blood sampling, this episode breaks down the technology in a simple, engaging way.
Understanding Continuous Glucose Monitors
Related Resources

Nigel Syrotuck breaks down REACH SVHC compliance for teams working with material suppliers and compliance questionnaires.

We examine when computational modelling and simulation, or CM&S, genuinely supports medical device simulation strategy and when it becomes a costly detour.

Many teams still underuse CM&S, often bringing it late in device validation, when key decisions have already been made. That approach leaves much of the value of CM&S untapped.

This article traces the Pennes bioheat equation from its 1948 origins to modern multiscale approaches, explaining how engineers select the right level of modelling complexity across device categories.